Cargando…

Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, maki...

Descripción completa

Detalles Bibliográficos
Autores principales: Krüger, Nadine, Kronenberger, Thales, Xie, Hang, Rocha, Cheila, Pöhlmann, Stefan, Su, Haixia, Xu, Yechun, Laufer, Stefan A., Pillaiyar, Thanigaimalai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959258/
https://www.ncbi.nlm.nih.gov/pubmed/37259339
http://dx.doi.org/10.3390/ph16020190
_version_ 1784895230706712576
author Krüger, Nadine
Kronenberger, Thales
Xie, Hang
Rocha, Cheila
Pöhlmann, Stefan
Su, Haixia
Xu, Yechun
Laufer, Stefan A.
Pillaiyar, Thanigaimalai
author_facet Krüger, Nadine
Kronenberger, Thales
Xie, Hang
Rocha, Cheila
Pöhlmann, Stefan
Su, Haixia
Xu, Yechun
Laufer, Stefan A.
Pillaiyar, Thanigaimalai
author_sort Krüger, Nadine
collection PubMed
description The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 M(pro). Several compounds were discovered to inhibit M(pro) at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 M(pro), and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.
format Online
Article
Text
id pubmed-9959258
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99592582023-02-26 Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19 Krüger, Nadine Kronenberger, Thales Xie, Hang Rocha, Cheila Pöhlmann, Stefan Su, Haixia Xu, Yechun Laufer, Stefan A. Pillaiyar, Thanigaimalai Pharmaceuticals (Basel) Article The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 M(pro). Several compounds were discovered to inhibit M(pro) at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 M(pro), and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research. MDPI 2023-01-28 /pmc/articles/PMC9959258/ /pubmed/37259339 http://dx.doi.org/10.3390/ph16020190 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Krüger, Nadine
Kronenberger, Thales
Xie, Hang
Rocha, Cheila
Pöhlmann, Stefan
Su, Haixia
Xu, Yechun
Laufer, Stefan A.
Pillaiyar, Thanigaimalai
Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
title Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
title_full Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
title_fullStr Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
title_full_unstemmed Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
title_short Discovery of Polyphenolic Natural Products as SARS-CoV-2 M(pro) Inhibitors for COVID-19
title_sort discovery of polyphenolic natural products as sars-cov-2 m(pro) inhibitors for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959258/
https://www.ncbi.nlm.nih.gov/pubmed/37259339
http://dx.doi.org/10.3390/ph16020190
work_keys_str_mv AT krugernadine discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT kronenbergerthales discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT xiehang discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT rochacheila discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT pohlmannstefan discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT suhaixia discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT xuyechun discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT lauferstefana discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19
AT pillaiyarthanigaimalai discoveryofpolyphenolicnaturalproductsassarscov2mproinhibitorsforcovid19